liquidbiopsyinfo.com
The LIQOMICS Liquid Biopsy Knowledge Base
Comprehensive, evidence-based information on liquid biopsy applications for minimal residual disease (MRD) detection and molecular profiling across 25 cancer types. Curated from peer-reviewed literature and clinical trial data to support informed clinical decision-making.
LIQOMICS Testing Solutions
LymphoVista
Specialized liquid biopsy solutions for lymphoma minimal residual disease monitoring and molecular profiling. Covering Hodgkin Lymphoma, DLBCL, and Follicular Lymphoma with high-sensitivity ctDNA detection optimized for hematologic malignancies.
CancerVista
Comprehensive ctDNA testing platform for solid tumors including MRD detection, treatment response monitoring, and actionable mutation profiling. Supporting precision medicine approaches across 20+ solid tumor types with validated clinical performance.
Evidence-Based Rankings: Top ctDNA Applications
Ranked by strength of clinical evidence, trial outcomes, and validation across independent studies
Understanding Evidence Badges:
- Level 1 RCT = Randomized Controlled Trial with clinical outcomes (highest level of evidence)
- NCCN Guidelines = Included in National Comprehensive Cancer Network clinical practice guidelines
- HR X.X = Hazard Ratio for recurrence, progression, or survival (higher values indicate stronger prognostic power)
- Prospective = Data from prospective clinical trials (forward-looking studies)
- Validation = Findings confirmed across multiple independent studies
Top MRD Detection Applications
Strongest Evidence for Minimal Residual Disease Monitoring
Bladder Cancer (MIBC)Level 1 RCT
IMvigor011 (NEJM 2025): First RCT proving ctDNA-guided immunotherapy improves DFS and OS. Exceptional HR >10 for recurrence risk.
Colorectal CancerLevel 1 RCT
DYNAMIC trial: ctDNA-guided therapy safely reduces unnecessary chemotherapy while maintaining excellent outcomes. HR 11.99 for recurrence.
Anal CancerHR 5.1
ACT II trial: Post-treatment ctDNA positivity HR 5.1 (95% CI 2.4-10.8, p<0.001) for progression. HPV DNA detection 98%. Excellent prognostic marker.
Laryngeal Cancer (HNSCC)HR 27.4
MAESTRO study: HR 27.4 for event-free survival (p<0.0001), HR 8.3 for OS. Lead time 7.0 months. NPV 91.7%. Multiple validation studies.
DLBCLNCCN Guidelines
Now in NCCN 2.2025 guidelines. HR 13.69 for end-of-treatment MRD. PFS 85% vs 15% (MRD- vs MRD+).
Endometrial CancerHR 6.2-25.4
Exceptional prognostic range. Recurrence: 52-58% (ctDNA+) vs 0-6% (ctDNA-). Lead time 3.1 months. RAINBO trials ongoing to validate predictive utility.
Cervical CancerHR 5.50-7.78
HPV ctDNA at 3 months post-treatment: HR 5.50-7.78 for recurrence. Lead time 164 days (5.6 months). 100% specificity. NPV 95%.
Lung Cancer (NSCLC)Multiple trials
Meta-analysis of 30 studies: HR 11.19 for PFS, 6.34 for OS. Median lead time 5.5 months. Validated across large cohorts.
Top Genotyping Applications
Strongest Evidence for Actionable Mutation Detection
Lung Cancer (NSCLC)NCCN 2025
ctDNA equivalent to tissue for complete genotyping. EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS G12C. 95% success rate.
Colorectal CancerFDA-approved uses
RAS, BRAF, HER2, MSI-H detection guide therapy selection. Multiple FDA-approved therapies based on ctDNA results.
Breast CancerClinical utility proven
ESR1 mutations (30-40%): PADA-1 showed treatment switching benefit. PIK3CA: Alpelisib FDA-approved.
Biliary Tract CancerExceptional survival
FGFR2 fusions: Futibatinib OS 123 vs 37 months. IDH1: Ivosidenib approved. 44% of patients have targetable alterations.
MelanomaBRAF V600E/K
~50% prevalence. Multiple approved targeted therapies (dabrafenib/trametinib). Treatment response monitoring validated.
Prostate CancerBRCA1/2/ATM
~20% mCRPC harbor HRR mutations. Olaparib FDA-approved. PROfound: PFS 7.4 vs 3.6 months for BRCA1/2.
Pancreatic CancerKRAS, BRCA1/2
KRAS >90% prevalence. BRCA1/2 germline 4-7%: Olaparib approved (POLO: PFS 7.4 vs 3.8 months).
Liver Cancer (HCC)Predictive
TERT promoter (51-61.5%): Predicts atezolizumab-bevacizumab response. Important for treatment selection.
Cancer-Specific Evidence Summaries
Comprehensive reviews of ctDNA testing applications across more than 20 cancers
Colorectal Cancer
Level 1 RCT evidence (DYNAMIC). HR 11.99. GALAXY study n=2,240. Lead time 4.8 months.
Lung Cancer (NSCLC)
NCCN 2025: ctDNA equivalent to tissue. Meta-analysis HR 11.19. 9+ actionable targets.
Breast Cancer
PADA-1 interventional trial. ESR1, PIK3CA validated. T-DXd approval based on ctDNA data.
Bladder Cancer (MIBC)
BREAKTHROUGH: IMvigor011 (NEJM 2025) first RCT proving ctDNA-guided therapy improves DFS/OS.
Pancreatic Cancer
KRAS >90%. BRCA1/2: Olaparib approved. Early detection ~2 months before imaging.
Gastric Cancer
HR 6-8 for recurrence. HER2 amplification ~20%. Lead time 3-4 months.
Esophageal Cancer
Neoadjuvant response prediction. HR ~8 for MRD positivity. HER2, PD-L1 detectable.
Prostate Cancer
BRCA1/2/ATM ~20% mCRPC. PARP inhibitors approved. AR variants guide resistance.
Liver Cancer (HCC)
TERT promoter 51-61%. Predicts atezolizumab response. Surveillance for recurrence.
Kidney Cancer (RCC)
Low shedder: 33% detection. VHL, PBRM1, BAP1 mutations. Angiogenesis pathway genes.
Endometrial Cancer
STRONGEST BIOMARKER: HR 15.5. Recurrence 52-58% vs 0-6%. MMRd/MSI-H ~30%.
Cervical Cancer
HPV ctDNA: HR 5.50-7.78 for recurrence. Lead time 164 days. Nearly 100% HPV DNA detectable.
Ovarian Cancer
HR 5.3-6.7 for PFS. Lead time 5.9-10 months. 93-100% baseline detection. MRD-: 24-28 months vs MRD+: 6-7 months PFS.
Hodgkin Lymphoma
High detection: 92-97% baseline sensitivity. MRD-: 88% vs 25% PFS. CD30 nearly universal.
DLBCL
NOW IN NCCN 2.2025. HR 13.69. PFS 85% vs 15%. GCB vs ABC classification.
Follicular Lymphoma
GALLIUM, SWOG trials. Epcoritamab + R2 approved Nov 2025: 79% risk reduction.
Anal Cancer
HR 5.1 for progression. Sensitivity 82-100%. HPV DNA detection 98%. Chemoradiation response.
Biliary Tract Cancer
FGFR2: OS 123 vs 37 months. IDH1 mutations. 44% targetable. Futibatinib, pemigatinib, ivosidenib approved.
Glioblastoma
CSF superior to plasma. EGFRvIII, TERT, IDH1. Detection rates 40-87% depending on method.
Laryngeal Cancer
HPV+ vs HPV-. ctDNA clearance predicts response. Lead time 2-4 months. Chemoradiation monitoring.
Oral Cavity & Throat Cancer
HPV status critical. MRD detection HR ~8. TP53 most common. Treatment response monitoring.
Sarcoma
Heterogeneous group. Fusion oncogenes detectable. Limited data but emerging promise.
Testicular Cancer
miR-371a-3p superior biomarker (90-92% sensitivity). ctDNA emerging. Resistance monitoring.
Thyroid Cancer
SEVERE LIMITATION: Only 25% detectable. RET fusions: Selpercatinib standard of care.
Melanoma
BRAF V600E/K ~50%. HR 2.9-7.9 for recurrence. Lead time 3-4 months. Resistance tracking.
Frequently Asked Questions
Common questions about liquid biopsy, ctDNA testing, and this knowledge base
What is liquid biopsy?
Liquid biopsy is a minimally invasive blood test that detects circulating tumor DNA (ctDNA) shed by cancer cells into the bloodstream. Unlike traditional tissue biopsies that require surgery, a liquid biopsy uses a simple blood draw to analyze tumor-derived genetic material. This enables real-time monitoring of cancer mutations, treatment response, and minimal residual disease (MRD) without invasive procedures.
What is MRD detection?
MRD (Minimal Residual Disease) detection identifies tiny amounts of cancer remaining after treatment that are too small to be seen on imaging scans. By detecting circulating tumor DNA in blood samples, MRD testing can reveal whether cancer cells persist months before clinical relapse becomes apparent. This early warning enables oncologists to make timely treatment decisions, potentially escalating therapy for high-risk patients or safely de-escalating for those who are truly disease-free.
How reliable is the evidence on this site?
All information on liquidbiopsyinfo.com is sourced from peer-reviewed publications, clinical trial data, and established medical guidelines (such as NCCN). The content is AI-assisted in its curation and structuring, which allows us to keep pace with the rapidly growing body of evidence. However, we are transparent about this approach and are actively building a continuous expert review process. This site is intended for educational purposes only and should not replace professional medical advice.
Which cancer types are covered?
We currently cover more than 25 cancer types with detailed evidence summaries, including colorectal, lung, breast, bladder, pancreatic, prostate, and ovarian cancers, as well as lymphomas (DLBCL, Hodgkin, Follicular) and rarer cancers like biliary tract, sarcoma, and glioblastoma. Each page summarizes the latest ctDNA evidence for MRD detection and molecular profiling. Browse all cancer types.
What are LymphoVista and CancerVista?
LymphoVista is LIQOMICS' specialized liquid biopsy testing solution for lymphoma, covering MRD monitoring and molecular profiling for Hodgkin Lymphoma, DLBCL, and Follicular Lymphoma. CancerVista is the comprehensive ctDNA testing platform for solid tumors, supporting MRD detection, treatment response monitoring, and actionable mutation profiling across 20+ solid tumor types.
Who is this knowledge base for?
This resource is designed for oncologists, hematologists, pathologists, medical researchers, and patients seeking evidence-based information about liquid biopsy and ctDNA testing. Whether you are a clinician evaluating MRD-guided treatment strategies or a patient wanting to understand the latest evidence for your cancer type, our goal is to make complex clinical data accessible and actionable.
General Questions
Test & Technology
Clinical Application
More Questions?
Visit our comprehensive FAQ or get in touch with our team directly.